News headlines about Akorn (NASDAQ:AKRX) have trended somewhat positive recently, Accern reports. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akorn earned a news impact score of 0.16 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.7988729686847 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Akorn (NASDAQ AKRX) opened at 33.15 on Thursday. The firm has a market capitalization of $4.14 billion, a price-to-earnings ratio of 33.48 and a beta of 1.38. Akorn has a one year low of $17.61 and a one year high of $34.00. The firm has a 50-day moving average price of $33.00 and a 200-day moving average price of $31.44.
A number of research firms recently weighed in on AKRX. Royal Bank Of Canada set a $34.00 target price on Akorn and gave the stock a “hold” rating in a report on Saturday, May 27th. Piper Jaffray Companies reissued a “hold” rating and set a $34.00 target price on shares of Akorn in a report on Thursday, August 10th. Zacks Investment Research lowered Akorn from a “hold” rating to a “strong sell” rating in a report on Friday, August 25th. BidaskClub raised Akorn from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $34.00 target price on shares of Akorn in a report on Wednesday, July 19th. Five equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $28.56.
In other Akorn news, Director Brian Tambi sold 5,165 shares of the firm’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $33.37, for a total value of $172,356.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Bruce Kutinsky sold 40,000 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $33.46, for a total value of $1,338,400.00. Following the completion of the sale, the chief operating officer now directly owns 317,480 shares of the company’s stock, valued at $10,622,880.80. The disclosure for this sale can be found here. Company insiders own 28.20% of the company’s stock.
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.